Literature DB >> 9649937

Changing the remodeling process in heart failure: basic mechanisms and laboratory results.

G S Francis1.   

Abstract

Heart failure continues to be a major source of death and disability, and concepts and understanding of the disorder continue to evolve. There is now widespread recognition that myocardial remodeling is an important driving force behind the progression of heart failure. Both scientists and clinicians strive to understand the remodeling process better. Several animal models have been helpful in this regard. Yet controversy and uncertainties persist regarding the fundamental mechanisms of cardiac remodeling. To appreciate better the contribution of diminished contractility to the syndrome of heart failure, a number of laboratories have studied isolated cardiac myocyte function, both in animal models and in humans with cardiomyopathy. Results have been mixed and contradictory. A consistent theme found in many studies, however, is that the cells assume a more elongated shape. There may or may not be concurrent incremental changes in myocyte transverse diameter, depending on the model under study. At least two groups have claimed that maximal contractile properties of myocytes isolated from human failing hearts and from animals with experimental heart failure are normal, but this may depend on where the cells are taken in reference to acute myocardial injury. There are some important model-specific considerations when interpreting the results of isolated myocyte studies. Nevertheless, such experiments reinforce the concept that structural changes during cardiac remodeling, including myocyte growth, deposition of collagen, cell dropout, and perhaps myocyte slippage, all contribute to the architectural changes in the geometry of the left ventricle. The quantitative contribution that each structural change makes is not yet entirely clear. Studies in humans suggest that myocyte elongation may be the dominant mechanism, but it cannot account for the disproportionate increase in chamber size relative to myocyte length. Therefore, myocyte slippage is likely making some contribution to cardiac remodeling. Whether the remodeling process can be reversed is currently a topic of great research interest. Preliminary data from studies of left ventricular assist devices and beta-adrenergic blockers suggest that attenuation of progression and perhaps even reversal of remodeling is possible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649937

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  9 in total

Review 1.  Novel Left Ventricular Assist System: an electrocardiogram-synchronized LVAS that avoids cardiac cannulation.

Authors:  Domingo Liotta
Journal:  Tex Heart Inst J       Date:  2003

2.  Atlas-Based Ventricular Shape Analysis for Understanding Congenital Heart Disease.

Authors:  Genevieve Farrar; Avan Suinesiaputra; Kathleen Gilbert; James C Perry; Sanjeet Hegde; Alison Marsden; Alistair A Young; Jeffrey H Omens; Andrew D McCulloch
Journal:  Prog Pediatr Cardiol       Date:  2016-08-18

Review 3.  Having a change of heart: reversing the suicidal proclivities of cardiac myocytes.

Authors:  Gerald W Dorn
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

Review 4.  Improvement of cardiac sarcoplasmic reticulum calcium cycling in dogs with heart failure following long-term therapy with the Acorn Cardiac Support Device.

Authors:  Ramesh C Gupta; Sudhish Mishra; Sharad Rastogi; Victor G Sharov; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

Review 5.  Mitochondrial pruning by Nix and BNip3: an essential function for cardiac-expressed death factors.

Authors:  Gerald W Dorn
Journal:  J Cardiovasc Transl Res       Date:  2010-03-16       Impact factor: 4.132

Review 6.  How cardiomyocytes sense pathophysiological stresses for cardiac remodeling.

Authors:  Zaffar K Haque; Da-Zhi Wang
Journal:  Cell Mol Life Sci       Date:  2016-10-06       Impact factor: 9.261

7.  Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray.

Authors:  J David Barrans; Paul D Allen; Dimitrios Stamatiou; Victor J Dzau; Choong-Chin Liew
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

8.  Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice.

Authors:  Vesna Nikolova; Christiana Leimena; Aisling C McMahon; Ju Chiat Tan; Suchitra Chandar; Dilesh Jogia; Scott H Kesteven; Jan Michalicek; Robyn Otway; Fons Verheyen; Stephen Rainer; Colin L Stewart; David Martin; Michael P Feneley; Diane Fatkin
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

9.  Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure.

Authors:  Seitaro Nomura; Masahiro Satoh; Takanori Fujita; Tomoaki Higo; Tomokazu Sumida; Toshiyuki Ko; Toshihiro Yamaguchi; Takashige Tobita; Atsuhiko T Naito; Masamichi Ito; Kanna Fujita; Mutsuo Harada; Haruhiro Toko; Yoshio Kobayashi; Kaoru Ito; Eiki Takimoto; Hiroshi Akazawa; Hiroyuki Morita; Hiroyuki Aburatani; Issei Komuro
Journal:  Nat Commun       Date:  2018-10-30       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.